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SELECTION OF THE MONTH 
Big Title: Transplantation reduces deaths of advanced ACLF patients 
 
Small titles:  
Estimating the impact of HCV chimera  
A new HDV mouse model 
 
LIVER INFLAMMATION AND FIBROSIS 
P2XY receptor signaling and the protective role of CD39 in sepsis, type II NKT 
cells drive inflammation, anti-fibrotic macrophage polarization  
The mechanism of liver injury and progressive cholestasis during sepsis is unknown. 
Extracellular ATP (eATP) is increased in sepsis and is known to trigger a pro-
inflammatory process through the purinergic receptor P2X 7 (hereafter P2X7) pathway. 
CD39 (also known as ectonucleoside triphosphate diphosphohydrolase 1, encoded by 
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ENTPD1) is known to scavenge eATP and generate adenosine, which limits P2X7 
activation and therefore, inflammation. In a series of elegant experiments in animal 
models, Savio et al. show for the first time that CD39 is important in limiting the 
severity of liver injury observed in sepsis by scavenging eATP. Their data support 
the development of novel strategies to augment CD39 expression to limit the 
deleterious effect of sepsis on the liver. 
T cells are usually viewed as being specific for peptide antigens that are presented on 
classical MHC molecules. However, many T cells actually respond to lipid-based 
antigens that are presented by the CD1 family of MHC-like molecules, which are 
typically expressed by professional antigen-presenting cells. The CD1 family is 
subdivided into at least three groups: group 1 comprises CD1a, CD1b and CD1c; group 
2 comprises CD1d; and group 3 comprises CD1e. The most extensively studied type 
of lipid-reactive T cell is the CD1d-restricted natural killer T (NKT) cell. The interaction 
between the NKT cell antigen receptor — i.e., the T cell receptor (TCR) expressed by 
NKT cells — and the antigen–CD1d complex is a central event leading to NKT cell 
activation. There are two main NKT cell subsets: type I NKT cells are typically 
characterized by the expression of a semi-invariant TCR, whereas the TCRs 
expressed by type II NKT cells are more diverse. Here Weng et al. report the results 
obtained in sophisticated transgenic mouse models designed to address the role of 
poorly-known role of type II NKT in the development of chronic liver inflammation. Their 
results unravel that an enhanced crosstalk between type II NKT cells and 
conventional T cells can give rise to a T helper 1-skewed inflammatory milieu, 
leading to the development of chronic autoimmune liver disease.  
Tissue macrophages are multifunctional and heterogeneous cell types which monitor 
local environment and maintain homeostasis. They express a broad array of sensing 
molecules, (e.g., pattern recognition receptors), which allows macrophages to monitor 
tissue microenvironments and act as sentinel cells for infection and tissue damage. In 
addition, macrophages perform many tissue-specific functions, which is reflected in 
their phenotypic diversity. Moreover, mature macrophages can undergo functional 
polarization in response to environmental signals. Two macrophage polarization 
programs are classically activated (M1) and alternative activated (M2) 
macrophages that are induced by different stimuli such as LPS plus interferon-γ and 
IL-4, respectively. Ma et al. polarized bone-marrow–derived macrophages into M1 or 
M2 phenotype and then administered these cells in different animal models of fibrosis. 
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They show that the administration of M1 macrophages, but not M2, is an effective 
cell therapy for experimental liver fibrosis. 
 
FATTY LIVER DISEASE 
Steatosis and fibrosis progression in HIV and germline mutations in the 
Hedgehog signaling and NAFLD. Liver disease are prevalent among HIV infected 
patients, in part due to high rate of Canadian cohort of unselected HIV- infected adults, 
the presence of steatosis and fibrosis was assessed by transient elastography and 
CAP. Prevalence of steatosis did not differ between HIV mono-infected and HIV/HCV 
co-infected patients. Interestingly, rate of steatosis progression was greater in HIV 
mono-infection and steatosis is associated with liver fibrosis progression in this cohort 
of patients. This study indicates that steatosis accelerates the rate of fibrosis 
progression in patients with HIV mono-infection. Manoeuvers aimed at decreasing 
steatosis (i.e. weight loss, alcohol abstinence, etc) are advised among HIV infected 
patients. In another study in this issue of Journal of Hepatology, interesting genetic 
determinants of NAFLD were uncovered. Activation of hedgehog (Hh) signaling has 
been implicated in the progression of NAFLD. In a translational study combining human 
and mice data, Guillen-Sacoto M et al studied the effect of germline mutations 
disrupting the Hh signaling pathway on NAFLD. In humans, the authors found that 
patients with holoprosencephaly (HPE), a disorder associated with germline mutations 
disrupting the Sonic Hh pathway, have increased incidence of NAFLD. The results 
were confirmed in mice with Hh signaling attenuation (Gli2 heterozygous null: Gli2+/-). 
Exposure of Gli2+/- mice to fatty liver-inducing diets resulted in increased liver 
steatosis compared to wild-type mice. Similar to humans, this effect was independent 
of obesity in the mutant mice and was associated with decreased expression of pro-
fibrotic and pro-inflammatory genes, and increased expression of PPAR, a potent anti-
fibrogenic regulator. This intriguing study suggest that germline mutations disrupting 
Hh signaling promote liver steatosis, independent of obesity. Further studies are 
required to evaluate the long-term effects of mutations affecting this pathway.  
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HEPATITIS C VIRUS (HCV) INFECTION 
To be 2 or not true 2 – Estimating the impact of HCV chimera, pooled safety of 
the 3D regimen in cirrhosis 
Inter-genotypic recombinant HCV strains containing genomic fragments of both 
genotype 2 and 1 will be misclassified as genotype 2 by standard genotyping methods, 
hence leading to inappropriate treatment decisions. In this issue of the Journal, Susser 
et al. provided the first large scale study evaluating the origin, prevalence and response 
to treatment of these HCV 2k/1b chimera. Whereas chimera frequency was 14% and 
25% in Germany and Israel, respectively, no chimeras were observed in Italy. 
Standard type 2 treatment with sofosbuvir plus ribavirin failed in HCV genotype 
2k/1b-infected patients, but genotype 1-based regimens were effective in 
eradicating the recombinant strains. Phylogenetic analyses revealed that migration 
flows from the former Soviet Union contributed to a relatively high number of the HCV 
genotype 2k/1b variant in Germany and Israel, and provide a basis for country and 
migration-based screening strategies to identify recombinant viruses. 
Although direct acting antivirals (DAAs) are considered safe in patients with chronic 
hepatitis C, benefit-risk profile may look differently in patients with already established 
cirrhosis. An international group of investigators headed by Poordad et al. should be 
congratulated for performing a comprehensive safety analysis of all 1,066 HCV-
infected patients with Child-Pugh A cirrhosis who have been treated in phase II and III 
trials with the combination regimen of ombitasvir, paritaprevir, and ritonavir, with or 
without dasabuvir (OBV/PTV/r ± DSV, i.e. 3D regimen). Serious treatment-emergent 
adverse events leading to study drug discontinuation were observed in 2.2%, 
and were consistent with hepatic decompensation in about half of them (1.2%). 
Risk factors for decompensation were evidence of more advanced compensated 
cirrhosis with low baseline albumin and HCV RNA levels as well as a prior history of 
non-selective beta-blocker use for varices. These data support the use of OBV/PTV/r 
± DSV ± RBV in patients with cirrhosis, but these regimens should be avoided in 
patients with a history of hepatic decompensation. 
 
HEPATITIS B VIRUS (HBV) INFECTION 
Alternative splicing modifies immune-mediated inflammation  
Immune escape represents a central mechanism for establishing viral persistence. 
Duriez et al. identified a novel mechanism how the crosstalk between virus and host 
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may contribute to this immune escape by altering the spliceosome machinery in HBV-
infected hepatocytes. Alternate splicing regulation of HBV transcripts leading to 
defective HBV circulating particles was already described more than 20 years ago, and 
considered playing a role in regulating viral replication but also liver disease 
progression. Now the authors report that alterations of the spliceosome 
machinery in HBV expressing cells are switched on by liver injury and enable a 
striking reduction in liver monocyte/macrophage recruitment. These findings 
reveal a novel paradigm whereby alternate splicing can generate a viral product able 
to inhibit immune-mediated inflammation and thereby down-modulate organ damage. 
The mechanism described in this elegant work may form a background for new 
immunotherapies facilitating HBV cure by targeting the immune tolerance established 
during chronic viral infection. 
 
HEPATITIS DELTA VIRUS (HDV) INFECTION 
A new mouse model to study HDV infection 
Drug development for chronic HDV infection – the most severe form of chronic viral 
hepatitis – is hampered by the limited availability of adequate immune competent small 
animal models. Suarez et al. described a new mouse model which mimics several 
important features of human HDV infection and disease. By the delivery of HDV- and 
HBV-replication competent genomes to the liver of immunocompetent adult 
mice (C57BL/6) via an adeno-associated virus vector, authors were able to 
establish sustained HDV replication leading to typical liver pathology with portal 
and lobular inflammation. Hence, this model represents an interesting tool that will 
allow testing of new antiviral strategies, studying the mechanism of pathogenesis, as 
well as the adaptive and innate immune responses to HDV infection. 
 
LIVER CANCER 
Tumor suppressor inhibition via histone-modifying enzyme activity, osteopontin 
as a biomarker of cholangiocarcinoma, dendritic cell-derived exosomes for HCC 
immunotherapy, 
Investigating histone-modifying enzymes in the context of hepatocellular carcinoma 
(HCC) is of major interest. Several distinct classes of enzymes can modify histone 
proteins at multiple sites; these include acetyltransferases, lysine (K) 
methyltransferases (KMTs), and lysine demethylases. Here we are interested in KMTs 
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that catalyze the transfer of one, two, or three methyl groups from S-adenosyl-L-
methionine SAM to the ε-amino group of a lysine residue on a histone to generate 
mono-, di-, and trimethylated histones. Their output can be either activation or 
repression of transcription. In this issue of the Journal, Wei et al. report results of their 
study of the histone-lysine N-methyltransferase EHMT2 (encoded by EHMT2, also 
known as G9a), which is known to catalyze methylation at K9 in histone 3, resulting in 
formation of heterochromatin (i.e., silent chromatin, which is “inaccessible” for 
transcription). They show EHMT2 upregulation in HCC which is due to 
downregulation of its inhibitor miR-1 and associated with disease progression 
and aggressive clinic pathological features. EHMT2 upregulation results in 
inhibition of the expression of retinoic acid receptor responder 3 (RARRES 3), a 
tumor suppressor. Therefore, EHMT2 expression could be a target for future 
therapeutic approaches in HCC. 
Integration of clinical, pathological, and molecular “orthogonal” data sets from patients 
with HCC is a challenge. Here Calderaro et al. show results of data integration which 
represent a new step toward the development of personalized medicine for HCC. They 
show that mutations in CTNNB1 (symbol for the catenin beta 1 gene) and TP53 
(symbol for the tumor protein p53 gene) are mutually exclusive, defining two 
major groups of HCC characterized by distinct phenotypes. For example, 
CTNNB1-mutated tumors are large, well-differentiated, cholestastic, with 
microtrabecular and pseudoglandular patterns and without inflammatory infiltrates. 
TP53-mutated tumors are poorly-differentiated with compact pattern, multinucleated 
and pleomorphic cells, and frequent vascular invasion. Interestingly, the transcriptome 
profile is also distinct between the two major mutated groups (subgroups 5-6 versus 
subgroups 1-3, respectively). These findings may help in translating our knowledge of 
HCC biology into clinical practice. 
Osteopontin (encoded by SPP1 [also known as OPN] belonging to the SIBLING gene 
family) is a secreted phosphoprotein which can be produced by biliary cells. Loosen et 
al. show here that serum osteopontin levels correlate with osteopontin upregulation in 
cholangiocarcinoma tumor cells and the tumor stroma. Moreover, pre- and 
postoperative elevations of osteopontin showed a striking association with poor 
postoperative survival. Therefore, measurements of serum osteopontin 
concentrations could be helpful to guide preoperative treatment decisions and 
to identify patients that particularly benefit from extended liver surgery. 
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Dendritic cell (DC)-derived exosomes (DEXs) form a new class of vaccines for cancer 
immunotherapy. Lu et al. provide interesting results on DEXs in three different HCC 
mouse models. They show that AFP-enriched DEXs can trigger potent antigen-
specific antitumor immune responses and reshape the tumor microenvironment 
in HCC mice and thus provide a cell-free vaccine option for HCC immunotherapy. 
 
LIVER TRANSPLANTATION 
Liver transplantation is feasible and effective in reducing mortality of ACLF 
patients 
Acute on chronic liver failure (ACLF) is a newly defined entity that complicates the 
course of relatively well patients with chronic liver disease and depending upon its 
severity can have 28-day mortality rates ranging from about 15% to over 80%. 
Treatment options for this condition are limited to supportive medical care and the role 
of transplantation is unknown. Louvet et al. report the results of a multicenter study 
assessing the outcomes of patients transplanted for severe ACLF (Grade 3) performed 
in France. Their remarkable study shows for the first time that the 1-year survival 
of patients with ACLF Grade 3 is similar to those with no ACLF (84% vs 90%). 
The 1-year survival of ACLF Grade 3 patients who were not transplanted was 
only 8%. These data are extremely provocative and likely to change clinical practice 
allowing these very sick patients to be considered as suitable candidates for 
transplantation. 
